TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06189391: An Open-Label, Dose Escalation Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-1045 (CN201) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Sponsor: MSD R&D (China) Co., Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,597,360

Rescue Site Savings

+$4,366,824

Unlock Full NCT06189391 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06189391 Rescue Dossier →